195 related articles for article (PubMed ID: 8559355)
1. Peripheral neuropathy secondary to docetaxel (Taxotere).
New PZ; Jackson CE; Rinaldi D; Burris H; Barohn RJ
Neurology; 1996 Jan; 46(1):108-11. PubMed ID: 8559355
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
Hilkens PH; Verweij J; Vecht CJ; Stoter G; van den Bent MJ
Ann Oncol; 1997 Feb; 8(2):187-90. PubMed ID: 9093729
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neurotoxicity induced by docetaxel.
Hilkens PH; Verweij J; Stoter G; Vecht CJ; van Putten WL; van den Bent MJ
Neurology; 1996 Jan; 46(1):104-8. PubMed ID: 8559354
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel neuropathy: a distal axonopathy.
Fazio R; Quattrini A; Bolognesi A; Bordogna G; Villa E; Previtali S; Canal N; Nemni R
Acta Neuropathol; 1999 Dec; 98(6):651-3. PubMed ID: 10603043
[TBL] [Abstract][Full Text] [Related]
5. Motor neuropathy due to docetaxel and paclitaxel.
Freilich RJ; Balmaceda C; Seidman AD; Rubin M; DeAngelis LM
Neurology; 1996 Jul; 47(1):115-8. PubMed ID: 8710063
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
Hilkens PH; Pronk LC; Verweij J; Vecht CJ; van Putten WL; van den Bent MJ
Br J Cancer; 1997; 75(3):417-22. PubMed ID: 9020489
[TBL] [Abstract][Full Text] [Related]
7. Lhermitte's sign following chemotherapy with docetaxel.
van den Bent MJ; Hilkens PH; Sillevis Smitt PA; van Raaij-van den Aarssen VJ; Bontenbal M; Verweij J
Neurology; 1998 Feb; 50(2):563-4. PubMed ID: 9484402
[TBL] [Abstract][Full Text] [Related]
8. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.
Persohn E; Canta A; Schoepfer S; Traebert M; Mueller L; Gilardini A; Galbiati S; Nicolini G; Scuteri A; Lanzani F; Giussani G; Cavaletti G
Eur J Cancer; 2005 Jul; 41(10):1460-6. PubMed ID: 15913989
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
Bissett D; Setanoians A; Cassidy J; Graham MA; Chadwick GA; Wilson P; Auzannet V; Le Bail N; Kaye SB; Kerr DJ
Cancer Res; 1993 Feb; 53(3):523-7. PubMed ID: 8093854
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
12. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
13. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
Piccart MJ; Gore M; Ten Bokkel Huinink W; Van Oosterom A; Verweij J; Wanders J; Franklin H; Bayssas M; Kaye S
J Natl Cancer Inst; 1995 May; 87(9):676-81. PubMed ID: 7752272
[TBL] [Abstract][Full Text] [Related]
15. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
Osmani K; Vignes S; Aissi M; Wade F; Milani P; Lévy BI; Kubis N
J Neurol; 2012 Sep; 259(9):1936-43. PubMed ID: 22349867
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients.
Ekholm E; Rantanen V; Bergman M; Vesalainen R; Antila K; Salminen E
Anticancer Res; 2000; 20(3B):2045-8. PubMed ID: 10928149
[TBL] [Abstract][Full Text] [Related]
17. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel for previously treated non-small-cell lung cancer.
Fossella FV
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.
van Oosterom AT; Schrijvers D; Schriivers D [corrected to Schrijvers D]
Anticancer Drugs; 1995 Jun; 6(3):356-68. PubMed ID: 7670133
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel-induced subungual hemorrhage.
Vanhooteghem O; André J; Vindevoghel A; Vandenbossche L; Vandeveire A; Song M
Dermatology; 1997; 194(4):419-20. PubMed ID: 9252781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
